// App-Quantinova.ai

e15010 : Efficacy and safety of regorafenib compared to TAS-102 for refractory metastatic colorectal cancer.

Researchers

Presenter

  • Ana Beatriz Kinupe Abrahao

Principal Investigators

  • Yoo-Joung Ko

  • Kelvin K. Chan

Medical Centers

  • Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Odette Cancer Center, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

  • Sunnybrook Odette Cancer Centre, University of Toronto, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Gastroenterology (GU)

Disease

  • Colorectal Cancer

Biomarkers

  • N/A

Drug/Treatment

  • Regorafenib

  • TAS102

Outcome

  • N/A

Study Design

  • Randomized

  • Controlled

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved